Abstract
Despite well-established pharmacological treatment, hypertension has remained a large contributor to noncommunicable deaths. Given the well-known association of hypertension with adverse cardiovascular disease the importance of blood pressure control has never been more crucial. Traditionally, pharmacological management has been the mainstay of care, however, with a growing burden of disease alternative and innovative approaches are now being considered. Minimally invasive catheter-based ablation systems, targeting renal sympathetic nerves, has been proposed as a more permanent way to control blood pressure. However, the clinical data supporting renal denervation has had many rises and falls throughout the years. With the promising results of the recent second-generation clinical trials there has been a renewed area of interest for renal denervation in the treatment of hypertension.
Original language | English |
---|---|
Pages (from-to) | 843-847 |
Number of pages | 5 |
Journal | Heart Lung and Circulation |
Volume | 30 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2021 |